These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36896214)

  • 1. Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era.
    Oertel M; Hering D; Nacke N; Kittel C; Kröger K; Kriz J; Fuchs M; Baues C; Vordermark D; Engenhart-Cabillic R; Herfarth K; Lukas P; Schmidberger H; Marnitz S; Borchmann P; Engert A; Haverkamp U; Eich HT
    Adv Radiat Oncol; 2023; 8(3):101169. PubMed ID: 36896214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group.
    Rosenbrock J; Kaul H; Oertel M; Celik E; Linde P; Fan J; Eichenauer DA; Bröckelmann PJ; von Tresckow B; Kobe C; Dietlein M; Fuchs M; Borchmann P; Eich HT; Baues C
    Int J Radiat Oncol Biol Phys; 2024 Apr; ():. PubMed ID: 38631539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
    Müller RP; Eich HT
    Strahlenther Onkol; 2005 Sep; 181(9):557-66. PubMed ID: 16170482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG).
    Kriz J; Baues C; Engenhart-Cabillic R; Haverkamp U; Herfart K; Lukas P; Plütschow A; Schmidberger H; Staar S; Fuchs M; Engert A; Eich HT
    Strahlenther Onkol; 2017 Feb; 193(2):109-115. PubMed ID: 27596217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy.
    Mulvihill DJ; McMichael K; Goyal S; Drachtman R; Weiss A; Khan AJ
    Radiother Oncol; 2014 Aug; 112(2):279-83. PubMed ID: 25082095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.
    Weber DC; Peguret N; Dipasquale G; Cozzi L
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1578-86. PubMed ID: 19596171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
    Weber DC; Johanson S; Peguret N; Cozzi L; Olsen DR
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):490-7. PubMed ID: 20800383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma.
    Verhappen MH; Poortmans PM; Raaijmakers E; Raemaekers JM
    Radiother Oncol; 2013 Oct; 109(1):133-9. PubMed ID: 24021344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT).
    Yahalom J
    Eur J Haematol Suppl; 2005 Jul; (66):90-7. PubMed ID: 16007875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trial.
    Oertel M; Hering D; Baues C; Kittel C; Fuchs M; Kriz J; Kröger K; Vordermark D; Herfarth K; Engenhart-Cabillic R; Lukas P; Haverkamp U; Borchmann P; Eich HT
    Front Oncol; 2023; 13():1183906. PubMed ID: 37213291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New quality assurance program integrating "modern radiotherapy" within the German Hodgkin Study Group.
    Kriz J; Baues C; Engenhart-Cabillic R; Haverkamp U; Herfarth K; Lukas P; Schmidberger H; Marnitz-Schulze S; Fuchs M; Engert A; Eich HT
    Strahlenther Onkol; 2017 Feb; 193(2):100-108. PubMed ID: 27678010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial.
    Baues C; Goergen H; Fuchs M; Rosenbrock J; Celik E; Eich H; Kobe C; Voltin CA; Engert A; Borchmann P; Marnitz S
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):900-906. PubMed ID: 34389407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
    Specht L; Yahalom J; Illidge T; Berthelsen AK; Constine LS; Eich HT; Girinsky T; Hoppe RT; Mauch P; Mikhaeel NG; Ng A;
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):854-62. PubMed ID: 23790512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
    Murray L; Sethugavalar B; Robertshaw H; Bayman E; Thomas E; Gilson D; Prestwich RJ
    Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):401-10. PubMed ID: 25840609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
    Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
    J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The radiotherapy reference panel--experiences and results of the German Hodgkin Study Group (GHSG).
    Eich HT; Müller RP
    Eur J Haematol Suppl; 2005 Jul; (66):98-105. PubMed ID: 16007876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma.
    Maraldo MV; Jørgensen M; Brodin NP; Aznar MC; Vogelius IR; Petersen PM; Berthelsen AK; Christensen CB; Hjalgrim LL; Specht L
    Pediatr Blood Cancer; 2014 Apr; 61(4):717-22. PubMed ID: 24660228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
    Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy.
    Filippi AR; Ragona R; Fusella M; Botticella A; Fiandra C; Ricardi U
    Pract Radiat Oncol; 2013; 3(3):216-222. PubMed ID: 24674367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
    Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.